NCT00964665View on ClinicalTrials.gov

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2010

Conditions
Chronic Hepatitis B
Interventions
DRUG

albinterferon alfa-2b

DRUG

albinterferon alfa-2b

DRUG

albinterferon alfa-2b

DRUG

albinterferon alfa-2b

DRUG

Pegasys®

Trial Locations (12)

Unknown

Novartis Investigator Site, Beijing

Novartis Investigator Site, Shatin

Novartis Investigator Site, Taipo

Novartis Investigator Site, Bialystok

Novartis Investigator Site, Lodz

Novartis Investigator Site, Warsaw

Novartis Investigator Site, Kaohsiung City

Novartis Investigator Site, Taipei

Novartis Investigator Site, Tau-Yuan County

Novartis Investigator Site, Bangkok

Novartis Investigator Site, Chiang Mai

Novartis Investigator Site, Songkhla

Sponsors
All Listed Sponsors
collaborator

Human Genome Sciences Inc.

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY